Dogwood Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DWTX research report →
Price Chart
About the company
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections.
- CEO
- Gregory Duncan
- IPO
- 2020
- Employees
- 8
- HQ
- Alpharetta, GA, US
Get TickerSpark's AI analysis on DWTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $54.14M
- P/E
- -0.18
- Fwd P/E
- 2.62
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.80
- EV/EBITDA
- -1.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -47.85%
- ROIC
- -35.62%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-27,968,445
- Net Income
- $-34,257,370-177.4%
- EPS
- $-4.32+65.5%
- OCF Growth
- -77.7%
- FCF Growth
- -77.7%
- 52W High
- $7.20
- 52W Low
- $1.28
- 50D MA
- $1.91
- 200D MA
- $2.25
- Beta
- 1.94
- RSI (14)
- 46
- Avg Volume
- 65.36K
No earnings-call transcripts are available for DWTX yet.
- Free Float
- 25.9%
- Shares Outstanding
- 33.63M
- Float Shares
- 8.71M
of shares held by institutions
13 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 3.13M | ▼ 147.51K |
| Millennium Management LLC | 341.81K | ▲ 341.81K |
| Vanguard Capital Management LLC | 132.15K | 0 |
| Geode Capital Management, LLC | 88.30K | ▲ 8.86K |
| Vanguard Fiduciary Trust Co | 62.74K | 0 |
| Vanguard Group Inc | 29.95K | ▲ 7.78K |
| Blackrock, Inc. | 28.55K | ▲ 28.52K |
| Northern Trust Corp | 23.78K | 0 |
| Citadel Advisors LLC | 11.74K | ▲ 11.74K |
| Tower Research Capital LLC (Trc) | 3.09K | ▼ 4.97K |
| Morgan Stanley | 2.22K | ▲ 2.22K |
| Ubs Group AG | 1.86K | ▼ 5.22K |
Held by 8 ETFs
Biggest fund positions in DWTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | De La Rosa Abel | other | 16,800 |
| Jun 16, 26 | Thomas John C | other | 16,800 |
| Jun 16, 26 | Whitley Richard James | other | 16,800 |
| Jun 16, 26 | Keefer David R | other | 16,800 |
| Mar 5, 26 | Grosswald Ralph | other | 82,500 |
| Mar 5, 26 | Walsh Angela | other | 82,500 |
| Mar 5, 26 | Gendreau Roger Michael | other | 82,500 |
| Mar 5, 26 | Duncan Gregory Scott | other | 330,000 |
| Dec 4, 25 | Duncan Gregory Scott | other | 460,000 |
| Dec 4, 25 | Walsh Angela | other | 150,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DWTX coverage
Recent articles, reports, and earnings notes.
No research on DWTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DWTX report →Dogwood to Participate in the 2026 Maxim Growth Summit
globenewswire.com · Oct 6
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
globenewswire.com · Sep 14
Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain Transcript
seekingalpha.com · Sep 2
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
marketbeat.com · Sep 1
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
globenewswire.com · Aug 17
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
globenewswire.com · Aug 13
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3% – What’s Next?
defenseworld.net · Aug 4
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
globenewswire.com · Jul 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.